The purpose of this study is to determine the PK/PD, efficacy and safety of GP2013 in patients with severe rheumatoid arthritis.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
AUC(0-inf) of GP2013, MabThera and Rituxan Following IV Infusion in Patients With RA
Timeframe: From baseline to 24 weeks